default author photo

Sheri Smith

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

64

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Phase 2 Study of Elraglusib (9-Ing-41), a Glycogen Synthase Kinase-3β Inhibitor, in Combination with Gemcitabine Plus Nab-Paclitaxel in Patients with Previously Untreated Metastatic Pancreatic Cancer

Number of pages: 40 Posted: 30 May 2024
Devalingam Mahalingam, Anwaar Saeed, Steven F. Powell, Marisol Huerta, Vaibhav Sahai, Andrew L. Coveler, Elizabeth J. Davis, Neeltje Steeghs, Mary Mulcahy, Alexander Raufi, Ludimila Cavalcante, Andrés Cervantes, Jordan Berlin, Taylor Weisskittel, Andrey Ugolkov, Andrew P. Mazar, William Mikrut, Sheri Smith, Francis J. Giles and Benedito A. Carneiro
affiliation not provided to SSRN, University of Kansas - Cancer Center, affiliation not provided to SSRN, INCLIVA Biomedical Research Institute, University of Michigan at Ann Arbor, Fred Hutchinson Cancer Research Center - Clinical Research Division, Vanderbilt University - Vanderbilt-Ingram Cancer Center, Netherlands Cancer Institute, Northwestern University - Northwestern Memorial Hospital, Brown University, Emory University - School of Medicine, INCLIVA Biomedical Research Institute, Vanderbilt University - Division of Hematology and Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Brown University
Downloads 64 (924,743)

Abstract:

Loading...

GSK-3β Inhibitor, elraglusib (9-ING-41), pancreatic cancer, combination, previously untreated